Iris Zohar

Dr. Iris Zohar

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2024 in CMI Communications
Verified
Journal Article
Open access
IZIris Zohar
Iris Zohar
YMYasmin Maor
Yasmin Maor
NSNeta Shirin
Neta Shirin
DYDafna Yahav
Dafna Yahav

27 September 2024 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Closed access
IZIris Zohar
Iris Zohar
DDDebby Ben David
Debby Ben David
OSOrna Schwartz
Orna Schwartz
APAdam Pomerantz
Adam Pomerantz
GCGabriel Caliari
Gabriel Caliari
YMYasmin Maor
Yasmin Maor
Background: Recently, breakpoints of Enterobacterales to amikacin were changed from MIC ≤ 16 mg/L to MIC ≤ 4 mg/L based mainly on laboratory data with little supporting clinical evidence. Our aim was to investigate the relation between MIC of Enterobacterales to amikacin and mortality among patients with Enterobacterales bacteraemia from a urinary tract source treated with amikacin. Patients and methods: This retrospective, single-centre study included patients with Enterobacterales urinary source bacteraemia treated with amikacin, with Low (MIC ≤ 4 mg/L) and High (MIC 8 or 16 mg/L) MICs. A cohort of patients treated with ertapenem was used to assess if amikacin MIC is a marker of severity independent of antimicrobial treatment. The primary outcome was 30-day mortality. Multivariate logistic regression analysis was done to assess risk factors for mortality. Results: We included 85 patients, 46 (54.1%) were male, and mean age was 79.0 years (SD 11.7). Sixty-one patients (71.8%) had Low MIC and 24 (28.2%) had High MIC. Thirty-day mortality was 8.2% and 29.2% in the Low and High MIC groups, respectively (P = 0.031). Risk factors for 30-day mortality were age, infection by Enterobacterales other than Escherichia coli and high amikacin MIC. In a cohort of 88 patients treated with ertapenem, amikacin MIC was not associated with 30-day mortality. Conclusions: We demonstrated a relation between higher amikacin MIC levels (8 and 16 mg/L) and increased 30-day mortality in patients treated with amikacin for bacteraemia secondary to a urinary source. These findings support the new CLSI breakpoint change of Enterobacterales to amikacin.

24 October 2024 in Infectious Disease Reports
Verified
Journal Article
Open access
PDF file
ZRZiv Rosman
Ziv Rosman
Yasmin MaorYasmin Maor
Yasmin Maor
IZIris Zohar
Iris Zohar
RBRonen Gingy Balmor
Ronen Gingy Balmor
MPMiri Schamroth Pravda
Miri Schamroth Pravda
ASArie Soroksky
Arie Soroksky
Sepsis is a life-threatening organ dysfunction syndrome caused by a dysregulated host response to infection that has a high mortality rate. Proprotein convertase subtilisin kexin 9 (PCSK9) is a serine protease secreted by the liver. Its binding to the low-density lipoprotein (LDL) receptor enhances its degradation, causing an increase in LDL levels in the blood. Objectives: Administering a PCSK9 inhibitor leading to an increase in lipid uptake by the liver may positively affect septic patients due to the increased removal of endotoxins. Methods: This preliminary study aimed to examine the safety of PCSK9 inhibitor use in septic and septic shock patients. We treated five septic patients in the intensive care unit with 300 mg of alirocumab following serious adverse events for 28 days. Results: Four of our patients did not experience any adverse events, and all of them survived. One patient died after discharge from the intensive care unit, and this death was presumably not related to the study drug. The patients rapidly recovered from the inflammatory stage of sepsis. Conclusions: Alirocumab appears safe in severe sepsis and septic shock patients. The outcome data are promising. Only a basic safety profile can be assessed based on this pilot study. Further study with a PCSK-9 inhibitor in septic or septic shock patients is required to further determine its benefit in ICU patients.

11 February 2022 in Journal of Community Medicine & Public Health
Verified
Journal Article
Open access
PDF file
IZIris Zohar
Iris Zohar
OSOrna Schwartz
Orna Schwartz
DDDebby Ben David
Debby Ben David
MMMargarita Mashavi
Margarita Mashavi
MAMohamad Aboulil
Mohamad Aboulil
Yasmin MaorYasmin Maor
Yasmin Maor
Background: Identifying hospitalized patients with Coronavirus disease 2019 (COVID-19) in a low prevalence setting is challenging. We aimed to identify differences between COVID-19 positive and negative patients. Methods: Hospitalized patients with respiratory illness, or fever, were isolated in the emergency room and tested for COVID-19. Patients with a negative PCR and low probability for COVID-19 were taken out of isolation. Patients with a higher probability for COVID-19 remained in isolation during hospitalization and were retested after 48 hours. Risk factors for COVID-19 were assessed using logistic regression. Results: 254 patients were included, 37 COVID-19-positive (14.6%) and 217 COVID-19-negative (85.4%). Median age was 76 years, 52% were males. In a multivariate regression model, variables significantly associated with COVID-19 positivity were exposure to a confirmed COVID-19 case, length of symptoms before testing, bilateral and peripheral infiltrates in chest X-ray, neutrophil count within the normal range, and elevated LDH. In an analysis including only patients with pneumonia (N=78, 18 positive for COVID-19), only bilateral and peripheral infiltrates, normal neutrophil count and elevated LDH were associated with COVID-19 positivity. Conclusions: The clinical presentation of COVID-19 positive and negative patients is similar, but radiographic and laboratory features may help to identify COVID-19 positive patients and to initiate quick decisions regarding isolation. Keywords: Respiratory symptoms; LDH; LDH; COVID-19; Emergency room

5 May 2026 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Closed access
IZIris Zohar
Iris Zohar
BSBaruch Satra-Shenes
Baruch Satra-Shenes
DMDvir Melloul
Dvir Melloul
OSOrly Satra-Shenes
Orly Satra-Shenes
APAdam Pomeranz
Adam Pomeranz
Yasmin MaorYasmin Maor
Yasmin Maor
Objectives: Aminoglycosides are historically considered nephrotoxic, though contemporary once-daily dosing and preferential amikacin use may reduce this risk. We evaluated the incidence and risk factors for acute kidney injury (AKI) among patients receiving amikacin. Methods: A retrospective cohort study of adult inpatients treated with amikacin between July 2018 and June 2022. Exclusion criteria were treatment 10 days, baseline eGFR <30 mL/min/1.73 m2, or insufficient renal follow-up. AKI was defined by KDIGO criteria. Charts of patients meeting AKI criteria were reviewed to assess likely aetiology. Multivariate logistic regression identified independent predictors. Results: Of 974 courses, 608 met the inclusion criteria. Patients had a median age of 81.0 years, 52.5% were female and the median baseline eGFR was 67.1 mL/min/1.73 m2. AKI occurred in 48 patients (7.9%), with KDIGO stage 2–3 in 14 (2.3%). Aetiologies included prerenal azotaemia (21%), shock/sepsis (35%), urinary obstruction (17%), contrast exposure (2.1%) and other nephrotoxic medications (2.1%); in 11 patients (22.9% of patients with AKI and 1.8% of the entire cohort), no alternative cause was identified. Multivariate analysis showed independent predictors of AKI were older age, longer interval from admission to treatment and discontinuation due to an infectious indication. Baseline eGFR, daily dose and treatment duration were not associated with AKI. Conclusions: In this contemporary cohort, we observed a relatively low incidence of AKI, often secondary to, or exacerbated by, other underlying causes. These findings suggest that once-daily amikacin may potentially carry a lower nephrotoxic risk than historically reported. Further studies are warranted to confirm safety in broader patient populations

17 September 2026 in Healthcare
Verified
Journal Article
Open access
PDF file
ANAmir Nutman
Amir Nutman
LOLiron Yosha Orpaz
Liron Yosha Orpaz
SOShirly Oren
Shirly Oren
Yasmin MaorYasmin Maor
Yasmin Maor
AGAdam Lee Goldstein
Adam Lee Goldstein
AEANAT ENGEL
ANAT ENGEL
Objective: On 7 October 2023, Hamas-led militants attacked Israeli communities bordering the Gaza Strip, abducting 251 people, including 201 civilians. Wolfson Medical Center was chosen by Israel’s Ministry of Health to care for repatriated civilians following a hostage release deal. We describe the development and implementation of a multidisciplinary care framework and report the clinical characteristics and short-term hospital outcomes of the repatriated civilians treated within it. Methods: A multidisciplinary framework was developed and implemented to address acute and chronic medical conditions, physical trauma, sexual assault, psychosocial support, and nutritional rehabilitation. Clinical characteristics and short-term hospital outcomes were retrospectively extracted from the electronic medical records. Results: Between 24 November and 1 December 2023, we treated 10 repatriated female hostages (median age 67 years, range 29–85 years) held captive for 48–55 days. They suffered physical trauma and loss of family members during the 7 October events. Captivity was associated with inadequate nutrition, poor hygiene, physical injuries, psychological distress, and insufficient management of chronic medical conditions. Acute conditions on arrival included rapid atrial fibrillation, heart failure, deep vein thrombosis, endocrine abnormalities, gastrointestinal symptoms and dermatologic conditions. Care required individualized planning, flexibility, and close coordination with national authorities, community health providers, and social services. Conclusions: Our experience highlights the need for comprehensive, coordinated care frameworks that not only address the medical, psychological, and social complexities of early recovery and reintegration but also ensure effective oversight and training of the medical teams involved.